NM-198
A Unique Combination of NoPass and Nano-in Technologies
NM-198:
What is NM-198?
NM-198 is Speratum Biopharma’s lead therapeutic candidate, a novel RNAi-based therapy arising from the combination of our innovative NoPass™ and Nano-in™ platforms.
Key Highlights:
- Innovative Design: Combines Nano-in delivery and NoPass RNAi design for precision targeting to transform the naturally-occurring tumor-suppressor microRNA miR-198 into a promising oncology therapeutic.
- Broad Applicability: Effective against multiple solid tumors, targeting factors involved in tumor growth, tumor spread, and resistance to chemotherapy.
- Efficient Delivery: Penetrates dense tumor microenvironments, including pancreatic stroma.
- Synergistic Therapy: Enhances chemotherapy efficacy, overcoming drug resistance.
- High Safety Profile: Non-toxic, no immune activation, and safe for long-term use.
- Scalable & Stable: Cost-effective manufacturing with long-term storage stability.
The Science Behind NoPass + Nano-in
The fusion of NoPass™ and Nano-in™ technologies makes NM-198 truly innovative:
The Journey of NM-198
- Experiments using cell lines demonstrate high efficiency in reducing cancer cell growth, migration, and resistance to chemotherapy, along with the concomitant silencing of tumor-promoting genes.
- Experiments conducted in animal models demonstrate a significant reduction in tumor burden and comorbidities when used as monotherapy against a broad range of solid tumors, along with a significant synergistic effect when combined with chemotherapy.
- Experiments conducted in both healthy mice and rats demonstrate safety in both short- and long-term dosing, even at high doses, as confirmed by hematology, blood chemistry, and histopathology results.
- Experiments conducted in ex vivo human blood demonstrate no unwanted immune response, as confirmed by the quantification of the 15 most important cytokines.
Summary of Results:
Pancreatic Cancer:
Combined with Gemcitabine, NM-198 reduced tumor growth dramatically in resistant pancreatic cancer models.
Ovarian Cancer:
Sensitized tumors to platinum-based therapies, reversing drug resistance.
Other Cancers:
Demonstrated efficacy in breast, colon, lung, kidney, gastric, and bone cancers.